Last edition
News about "Asahi Kasei Pharma "
Asahi Kasei Pharma Secures Global License from Alchemedicine to Strengthen Autoimmune Pipeline
Asahi Kasei Pharma has expanded its drug discovery pipeline through an exclusive global licensing agreement with Alchemedicine for novel lead compounds targeting a single, undisclosed mechanism.
Asahi Kasei Pharma | 27/02/2026 | By Darshana
Asahi Kasei Pharma Signs Exclusive License Deal for Anti-CX3CR1 Antibody
The anti-CX3CR1 antibody, currently in preclinical development, works by inhibiting CX3CR1, a receptor involved in immune cell migration to inflammatory sites.
Asahi Kasei Pharma | 12/12/2024 | By Aishwarya | 259
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy